Injection

Injection is the delivery of a substance by needle, placing it directly into the body in a way that bypasses the gastrointestinal tract entirely. Depending on the target tissue, three routes are distinguished: intravenous (into a vein), intramuscular (into muscle), and subcutaneous (under the skin, into the fatty layer between skin and muscle).

Clinically, all three are grouped under the term parenteral administration — meaning "outside the gut." Each reaches circulation by a different path, and their absorption characters and risk profiles differ accordingly.

Onset & absorption

Because injection skips the gut, first-pass metabolism does not apply: the liver does not process the compound before it reaches the rest of the body, and more of the substance arrives in circulation than an equivalent oral dose would deliver.

Intravenous injection is the fastest route in common use. A substance placed directly into a vein reaches the brain with almost no delay; effects arrive abruptly, the rise is steep, and the peak comes quickly. Intramuscular injection is slower — the compound must diffuse from muscle tissue into surrounding capillaries before entering general circulation — and the onset is more gradual than IV, though still considerably faster than oral dosing. Subcutaneous injection is slower still, absorbed through the capillary bed beneath the skin.

That abruptness carries a practical consequence that goes beyond speed: a steep rise leaves very little time to intervene if something goes wrong.

Harm reduction

The needle punctures a physical barrier the body maintains against the outside world, and this creates a class of risks that belong to the route rather than to any substance.

Infection is the most pervasive. Unsterile technique, reused needles, or shared equipment introduces bacteria and viruses directly into tissue or the bloodstream. Bloodborne pathogens — including hepatitis B, hepatitis C, and HIV — transmit efficiently through shared injection equipment; this risk applies equally across all three subtypes.

Repeated intravenous use damages veins progressively: scarring, thrombosis, and eventual collapse of accessible sites are well-documented consequences of long-term IV use. Intramuscular and subcutaneous injection carry a risk of abscess at the injection site, particularly when technique is imperfect or the compound is caustic to tissue. Embolism — obstruction of a vessel by an air bubble, an undissolved particle, or an oil-based carrier — is a specific hazard of intravenous injection with anything not formulated for that route.

The speed of IV delivery reduces the practical margin for error: there is no absorption phase to interrupt if the dose is miscalculated or an adverse reaction begins to develop.

What varies by substance

Injection as a route does not determine the character of the experience, its duration, or the specific risks a compound carries. Those belong to the substance itself.

Whether a substance is safe to inject at all is a compound-level question. Solubility, pH, and the nature of any binders, fillers, or solvents present all matter: a compound not formulated for parenteral use may contain excipients that cause serious harm when introduced into tissue or the bloodstream.

The practical difference between subcutaneous, intramuscular, and intravenous delivery also varies by substance — for some compounds the distinction in onset is pronounced; for others it is modest. The real values — bioavailability, timing, interaction risks, and any guidance on safer administration — live on the substance record, where they can be traced to their source.